



## Knockdown of circRNA circ\_0087378 Represses the Tumorigenesis and Progression of Esophageal Squamous Cell Carcinoma Through Modulating the miR-140-3p/E2F3 Axis

#### **OPEN ACCESS**

#### Edited by:

Peixin Dong, Hokkaido University, Japan

#### Reviewed by: Lin Fu.

Lin ru, Second Affiliated Hospital of Guangzhou Medical University, China Daozhi Xu, Shenyang Medical College, China

#### \*Correspondence:

Yongshun Chen yongshun81338@163.com Shaobo Ke zmnxbcv156@163.com Haoliang Zhang haoliangzhang@aliyun.com

#### Specialty section:

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Received: 16 September 2020 Accepted: 16 December 2020 Published: 12 February 2021

#### Citation:

Wang J, Wang Q, Gong Y, Hu Q, Zhang H, Ke S and Chen Y (2021) Knockdown of circRNA circ\_0087378 Represses the Turnorigenesis and Progression of Esophageal Squamous Cell Carcinoma Through Modulating the miR-140-3p/E2F3 Axis. Front. Oncol. 10:607231. doi: 10.3389/fonc.2020.607231 Jing Wang<sup>1</sup>, Qiushuang Wang<sup>2</sup>, Yi Gong<sup>1</sup>, Qiu Hu<sup>1</sup>, Haoliang Zhang<sup>3\*</sup>, Shaobo Ke<sup>1\*</sup> and Yongshun Chen<sup>1\*</sup>

<sup>1</sup> Department of Clinical Oncology, Renmin Hospital of Wuhan University, The First Clinical College of Wuhan University, Wuhan, China, <sup>2</sup> Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, The First Clinical College of Wuhan University, Wuhan, China, <sup>3</sup> Department of Oncology, Tangshan Workers' Hospital, Tangshan, China

**Background:** We aimed to investigate the function and underlying mechanisms of circ\_0087378 in esophageal squamous cell carcinoma (ESCC).

**Methods:** We verified higher circ\_0087378 expression in ESCC tissues by performing qRT-PCR assays. We further confirmed the oncogenic roles of circ\_0087378 in ESCC cells through a series of biological function assays. Then, we used an RNA pull-down assay and luciferase reporter assay to identify miR-140-3p that directly interacts with circ\_0087378. Subsequent studies were performed to demonstrate that the circ\_0087378/miR-140-3p/E2F3 axis promotes ESCC development.

**Results:** We demonstrated that upregulated circ\_0087378 expression was positively associated with tumor size, histological grade, tumor stage, the presence of metastasis, and worse survival in patients with ESCC. Our results further revealed that knockdown of circ\_0087378 suppressed the proliferation, migration, and invasion of ESCC cells and reduced tumor growth *in vivo*. Mechanistically, we showed that circ\_0087378 could directly bind to miR-miR-140-3p and relieve the suppression for target E2F3, which accelerated cell proliferation, migration, and invasion. Correlation analysis in ESCC specimens supported the involvement of the circ\_0087378/miR-140-3p/E2F3 axis in ESCC progression.

**Conclusions:** This study demonstrated that circ\_0087378 might act as a competing endogenous RNA for miR-140-3p, which could inhibit the tumorigenesis and progression of ESCC through upregulating E2F3 expression.

Keywords: esophageal squamous cell carcinoma, circ\_0087378, miR-140-3p, E2F3, cancer progression

## INTRODUCTION

Esophageal cancer (EC) is one of the most common malignancies worldwide (1, 2). There has been a dramatic rise in the incidence of EC in the developed world over the last 30 years (3). The vast majority of ECs occur as either squamous cell carcinomas (ESCCs) or adenocarcinomas (4, 5). ESCCs account for approximately 90% of EC cases (4, 5). Owing to the lack of inconspicuous early symptoms, most ESCC patients are diagnosed at late-stages (6, 7). Therefore, a better understanding of the molecular mechanisms that drive tumorigenesis and progression in ESCC is critical to develop more effective anti-ESCC treatments.

In recent years, the involvement of small non-coding RNAs, such as circular RNAs (circRNAs) and microRNAs (miRNAs), in ESCC development is increasingly appreciated (8, 9). MiRNAs control gene expression by binding to a complementary sequence in the 3'-untranslated region (3'-UTR) of target mRNAs (10). Until now, miRNAs have been extensively studied in ESCC, where they may be dysregulated and act as biomarkers or therapeutic targets (8, 9). On the other hand, the participation of circRNAs in ESCCs is much less well-established (8, 9). Emerging evidence suggests that some circRNAs function as miRNA sponges to trap miRNA involved in tumorigenesis and metastasis (8, 9). It has been reported that circLPAR3 could target miR-198 to promote ESCC metastasis (11). CircRNA 001275 is a sponge of miR-370-3p to enhance cisplatin resistance in ESCC (12). CircPVT1 could target miR-4663 to promote EC proliferation (6). Circ\_0087378 is a newly identified circRNA in breast cancer (13). To date, however, the functions and mechanisms of circ\_0087378 in ESCC remain largely unknown.

MiR-140-3p was reported to suppress the malignant properties in colorectal cancer (14), breast cancer (15), and lung cancer (16). However, the role and potential target genes of miR-140-3p in ESCC is still poorly understood. Moreover, E2F3, an important member of the E2F family has been reported to have critical roles in regulating cell cycle, cell differentiation, and apoptosis of human cancer cells (17-19). Accumulating data demonstrated that the LINC00467-miR-200a-E2F3 axis was implicated in the regulation of glioma cell tumorigenesis (20). Additionally, circPRMT5 sponges miR-377 to increase the expression of E2F3 in colorectal cancer (21). However, there are no previous reports that address the function of E2F3 in ESCC. In this study, we have proved that circ\_0087378, as a newly discovered circRNA in ESCC, could sponge miR-140-3p to upregulate the expression of E2F3 and eventually serve as a tumor promotor in ESCC.

#### MATERIALS AND METHODS

#### Patient Samples

This study has been approved by the Medical Ethics Committee of Wuhan University People's Hospital and conformed to the declaration of Helsinki. A cohort of ESCC tissues and matched normal tissues was derived from 50 patients with ESCC. These patients did not receive radiotherapy or chemotherapy before surgery. All patients provided their informed consent in writing before they participated in this study. Tumor tissues and adjacent non-cancerous tissues were stored at a  $-80^{\circ}$ C freezer.

### **Cell Lines and Culture Conditions**

The ESCC cell lines (KYSE41, EC109, EC9706, KYSE150, and KYSE30) and the immortalized human esophageal epithelial cell line SHEE were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Solarbio, China) supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin, and penicillin at 37°C in 5% CO2.

#### **Lentiviral Vectors and Transfection**

Short hairpin RNAs (shRNA) targeting circ\_0087378 (circ\_0087378#1 and sh-circ\_0087378#2) and the negative control shRNA (shNC) were obtained from GenePharma (Shanghai, China). All shRNA sequences were listed in Table 1. HEK-293T cells were co-transfected with the shRNA plasmids, psPAX2, and pMD2.G. The supernatant containing the lentivirus particles was used to infect EC109 or KYSE150 cells for 48 h, and transduced cells were selected by addition of puromycin (2 µg/ml; Sigma-Aldrich, USA). The negative control miRNA mimic (miR-NC) and miR-140-3p mimic (miR-140-3p), negative control miRNA inhibitor (anti-miR-NC) and miR-140-3p inhibitor (anti-miR-140-3p) were purchased from GenePharma. Full-length cDNA of E2F3 was inserted into the pcDNA3.1 vector to generate the E2F3 overexpression plasmid (Honorgene, Changsha, China). MiRNA mimic, miRNA inhibitor, and plasmids were transfected using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

# Quantitative Real-Time PCR (qRT-PCR) Assay

TRIzol reagent was purchased from Invitrogen (Carlsbad, CA, USA) and employed to isolate total RNAs. Reverse Transcriptase Kit was obtained from Takara (Beijing, China) and employed to reverse transcribed the circRNA and mRNA. Total RNA was also reverse-transcribed by a MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The qRT-PCR assays were performed as previously reported (12). GAPDH and U6 were used as internal controls for circRNAs and miRNAs, respectively. All primer sequences were listed in **Table 2**.

TABLE 1 | shRNA sequence for human circ\_0087378.

| Primer sequence (5'-3') |  |  |  |
|-------------------------|--|--|--|
| UUCUCCGAACGUGUCACGUTT   |  |  |  |
| GGCATGAAAGGTGCAAACCCA   |  |  |  |
| GCATGAAAGGTGCAAACCCAA   |  |  |  |
|                         |  |  |  |

#### **TABLE 2** | Primers used for qRT-PCR assay.

| Target          | Primer sequence (5'-3')  |  |  |  |
|-----------------|--------------------------|--|--|--|
| circ_0087378-hF | TCTCGGTCTATGCTGTGGTG     |  |  |  |
| circ_0087378-hR | CATTCGCTGCAGTTCCATAA     |  |  |  |
| miR-140-3p-hF   | CAGTGCTGTACCACAGGGTAGA   |  |  |  |
| miR-140-3p -hR  | TATCCTTGTTCACGACTCCTTCAC |  |  |  |
| E2F3-hF         | TATCCCTAAACCCGCTTCC      |  |  |  |
| E2F3-hR         | TTCACAAACGGTCCTTCTA      |  |  |  |
| GAPDH -hF       | TGAACGGGAAGCTCACTGG      |  |  |  |
| GAPDH -hR       | TCCACCACCTGTTGCTGTA      |  |  |  |
| U6-hF           | CTCGCTTCGGCAGCACA        |  |  |  |
| U6-hR           | AACGCTTCACGAATTTGCGT     |  |  |  |

#### RNase R Treatment

RNase R (Epicentre Company) was used to eliminate the linear RNA. The expression of GAPDH and circ\_0087378 was assessed using qRT-PCR assays.

#### **Cell Proliferation Assay**

Cell proliferation test was performed according to CCK-8 manuscript on day 0, day 1, day 2, and day 3 after transfection.

#### **Colony Formation Assay**

EC109 or KYSE150 cells  $(1 \times 10^3/\text{well})$  were seeded into a sixwell plate. After 14 days, cells were fixed with 4% paraformaldehyde and then stained by 0.1% crystal violet. After that, the number of clones was counted and analyzed.

#### **Cell Migration and Invasion Assays**

Transwell cell migration and invasion assays were carried out as previously described (22). In brief, EC109 or KYSE150 cells  $(1 \times 10^5)$  were added to the upper chambers of transwell plates. The lower chambers were filled with 750 µl of RPMI-1640 medium containing 10% FBS. After an incubation period of 24 h, the migrated or invaded cells were stained by 0.1% crystal violet for 30 min. The number of cells was calculated from 10 random fields in each chamber.

#### **Flow Cytometry Analysis**

EC109 or KYSE150 cells  $(1 \times 10^5/\text{well})$  were harvested and stained using an Annexin V-FITC apoptosis detection kit (Solarbio). The cells were then analyzed using a FACSCalibur flow cytometer (BD Biosciences, USA).

#### **ESCC Xenograft Mouse Model**

Fifty 6–8 weeks old BALB/c nude mice (20 g) were purchased from Shanghai Laboratory Animals Center (China) and employed to establish the mouse models as previously reported (23). In brief,  $2 \times 10^5/20 \,\mu$ l of ESCC cells were subcutaneously injected into the nude mice. The tumor volume of each mouse was measured every 7 days. All procedures and animal experiments were approved by the Animal ethics committee of Wuhan University.

#### Dual-Luciferase Reporter Assay, RNA Pull-Down Assay, and RIP Assay

The Dual-luciferase reporter gene assay, RNA pull-down and RIP assays were performed as previously described

(24, 25). Briefly, the luciferase reporter plasmids containing circ\_0087378-wild type (WT), circ\_0087378-muatnt (MUT), E2F3-WT or E2F3-MUT were produced from the pmirGLO vectors (Promega, Madison, WI, USA). Primer sequences were as follows: circ\_0087378-WT (Forward primer: 5'-GGAA TTCCTGTGGTGGTGGTGATTGCGTCTGTGGT-3'; Reverse primer: 5'-CCAAGCTTGG CTTTCATGCCAAACTTGGAG TG-3'), circ\_0087378-MUT (Forward primer: 5'-GGAATTCC TGTGATAATGATTGCGTTTATGGT-3'; Reverse primer: 5'-CCAAGCTTGG CTTTCATGCCAAACTTGGAGTG-3'), E2F3 3'-UTR-WT (Forward primer: 5'-GGAATTCCGGTACAAAA TGTCGGTGTGGTC-3'; Reverse primer: 5'-CCAAGCTTGG GCCAGGTGAGCTCAGTCTTT-3'), and E2F3 3'-UTR-MUT (Forward primer: 5'-GGAATTCCGGTACAAAATGTCGGTC TAGCC-3'; Reverse primer: 5'-CCAAGCTTGGGCCAGGT GAGCTCAGTCTTT-3'). EC109 or KYSE150 cells were cotransfected with the above reporter plasmids, with miR-140-3p mimic or miR-NC, respectively. The luciferase signal was measured using a Dual-Luciferase Reporter Assay System (Promega). EC109 or KYSE150 cells were transfected with the biotin-labeled circ\_0087378 (Bio- circ\_0087378-wt) or the respective control. Cells were digested after 48 h, and streptavidin magnetic beads were used to incubate the lysates. The expression of miR-140-3p was measured by qRT-PCR assay. RIP was performed using an EZ-Magna RIP Kit (Millipore, Billerica, MA, USA). EC109 or KYSE150 cells were lysed using the RIP lysis buffer (Sigma-Aldrich, USA). Magnetic beads coupled with anti-immunoglobulin G (IgG) or anti-Argonaute 2 (AGO2) were employed to incubate cell lysates. The expression of circ\_0087378 and miR-140-3p in immunoprecipitated RNAs were assessed by qRT-PCR assay.

#### Western Blotting Analysis

EC109 and KYSE150 cells were lysed by RIPA lysis buffer (Beyotime, Shanghai, China) The protein was isolated and transferred onto PVDF membranes as previously described (26). After blocking 5% milk, the membranes were incubated with primary antibodies (**Table 3**). Then the membranes were incubated with the secondary antibodies. Immunoblot signals were visualized using the EasyBlot ECL kit (Sangon Biotech, China). Detected bands were quantified using ImageJ software (Rawak Software, Inc. Germany).

#### **Statistical Analysis**

Statistical analysis was performed using SPSS 21.0 software (IBM, USA). All the experiments were repeated three times. All values were presented as means  $\pm$  standard deviation (SD). The difference was calculated by the Student's *t*-tests, the  $\chi^2$ -tests and one-way ANOVA analysis. Kaplan-Meier analysis was used to evaluate overall survival, and a Spearman correlation

TABLE 3 | List of antibodies used in western blotting analysis.

| Antibody Name        | Company | Dilution |  |  |
|----------------------|---------|----------|--|--|
| Anti-E2F3 (ab152126) | Abcam   | 1:2,000  |  |  |
| Anti-GAPDH (ab9484)  | Abcam   | 1:2,000  |  |  |

coefficient was used to analyze correlations. A *P*-value of <0.05 was considered statistically significant.

#### RESULTS

#### Circ\_0087378 Is Upregulated in ESCC Tissues and Higher circ\_0087378 Was Correlated With Poorer Outcomes in ESCC Patients

In order to seek for circRNAs aberrantly expressed in ESCC, we analyzed the GEO dataset (GSE131969) containing three ESCC tissues and three normal tissues and found that circ\_0087378 is highly expressed in ESCC tissues relative to adjacent normal tissues (Figure 1A). By using the qRT-PCR assays, we verified the upregulation of circ\_0087378 expression in ESCC tissues compared with adjacent normal tissues (Figure 1B). Consistent with these results, we found that higher circ\_0087378 expression was positively correlated with tumor size, histological grade, tumor stage, and the presence of metastasis in patients with ESCC (Table 4). Based on the median expression value of circ\_0087378 in 50 ESCC cancer tissues, patients were divided into circ\_0087378-low expression group and circ\_0087378-high expression group. Kaplan-Meier survival analysis showed that patients with higher circ\_0087378 levels displayed lower overall survival rates (Figure 1C).

Then, we assessed the expression of circ\_0087378 in various ESCC cell lines. Circ\_0087378 expression was significantly higher in human ESCC cell lines than that in human

esophageal epithelial cell line SHEE (**Figure 1D**). Compared to linear GAPDH mRNA, circ\_0087378 was found to be resistant to RNase R (**Figure 1E**). We further analyzed the subcellular location of circ\_0087378. Our results suggested that circ\_0087378 was mainly located in the cytoplasm (**Figure 1F**). Taken together, our data supported that circ\_0087378 was highly expressed in ESCC, and higher circ\_0087378 was correlated with poorer outcomes in ESCC patients.

## Knockdown of circ\_0087378 Suppresses ESCC Progression *In vitro* and *In Vivo*

Of the ESCC cell lines, circ\_0087378 expression was highest in the EC109 and KYSE150 cell lines (**Figure 1D**), which were selected for subsequent circ\_0087378-knockdown experiments. Short hairpin RNAs (shRNA) targeting the back-spliced section of circ\_0087378 (sh-circ\_0087378#1 and sh-circ\_0087378#2) were generated to effectively knockdown circ\_0087378 expression in EC109 and KYSE150 cells (**Figure 2A**).

We next evaluated the biological role of circ\_0087378 in ESCC. The results demonstrated that depletion of circ\_0087378 with shRNAs could significantly inhibit the proliferation, migration, and invasion of ESCC cell lines (**Figures 2B-E**). Flow cytometry analysis showed that knockdown of circ\_0087378 in ESCC cells significantly induced cell apoptosis (**Figure 2F**). Also, we established a nude mice model of ESCC by subcutaneous inoculation of ESCC cells transfected sh-circ\_0087378#1 or mock cells. We found that the downregulation of circ\_0087378 resulted in a significantly lower tumor size and weight compared with controls (**Figures 2G, H**). These data suggested that silencing





| Factor                | circ_0087378 expression |               | P value | miR-140-3p expression |               | P value | E2F3 expression |               | P value |
|-----------------------|-------------------------|---------------|---------|-----------------------|---------------|---------|-----------------|---------------|---------|
|                       | Low (n = 25)            | High (n = 25) |         | Low (n = 25)          | High (n = 25) |         | Low (n = 25)    | High (n = 25) |         |
| Age                   |                         |               | 0.395   |                       |               | 0.156   |                 |               | 0.284   |
| ≤65                   | 15                      | 12            |         | 16                    | 11            |         | 13              | 14            |         |
| >65                   | 10                      | 13            |         | 9                     | 14            |         | 12              | 11            |         |
| Gender                |                         |               | 0.569   |                       |               | >0.99   |                 |               | 0.087   |
| Male                  | 13                      | 15            |         | 14                    | 14            |         | 11              | 17            |         |
| Female                | 12                      | 10            |         | 11                    | 11            |         | 14              | 8             |         |
| Tumor size            |                         |               | 0.024   |                       |               | 0.258   |                 |               | 0.005   |
| ≤2cm                  | 16                      | 8             |         | 10                    | 14            |         | 17              | 7             |         |
| >2cm                  | 9                       | 17            |         | 15                    | 11            |         | 8               | 18            |         |
| Tumor differentiation |                         | 0.004         |         |                       | 0.001         |         |                 | 0.023         |         |
| Well                  | 16                      | 6             |         | 5                     | 17            |         | 15              | 7             |         |
| Poor                  | 9                       | 19            |         | 20                    | 8             |         | 10              | 18            |         |
| TNM stage             |                         |               | 0.048   |                       |               | 0.011   |                 |               | 0.019   |
| 1/11                  | 16                      | 9             |         | 6                     | 19            |         | 18              | 7             |         |
| III/IV                | 9                       | 16            |         | 19                    | 6             |         | 7               | 18            |         |
| Lymph node me         | etastasis               |               | 0.012   |                       |               | 0.002   |                 |               | 0.529   |
| Negative              | 22                      | 14            |         | 16                    | 20            |         | 19              | 17            |         |
| Positive              | 3                       | 11            |         | 9                     | 5             |         | 6               | 8             |         |
| Distant metasta       | sis                     |               | < 0.001 |                       |               | 0.005   |                 |               | 0.031   |
| Yes                   | 2                       | 13            |         | 18                    | 8             |         | 4               | 11            |         |
| No                    | 23                      | 12            |         | 7                     | 17            |         | 21              | 14            |         |

TABLE 4 | Correlations of circ\_0087378, miR-140-3p, and E2F3 expression with clinicopathologic features of esophageal squamous cell carcinoma.

of circ\_0087378 significantly inhibited the progression of xenograft tumors possibly through inducing apoptosis *in vivo*.

# Circ\_0087378 Sequesters MiR-140-3p in ESCC Cells

Given that circRNAs have been reported to act as miRNA sponges (8, 9), we wonder whether circ\_0087378 can bind to certain miRNAs in the progression of ESCC. We predicted the miRNAs that might target circ\_0087378 by analyzing the StarBase and CircInteractome databases. We then selected the top three miRNAs (including miR-140-3p, miR-431-5p, and miR-432-5p) based on conjugation scores (Figure 3A). Our qRT-PCR assays determined that knocking down circ\_0087378 in ESCC cells significantly upregulated the expression of miR-140-3p (but not the remaining two miRNAs) (Figure 3B). Subsequently, we confirmed the downregulation of miR-140-3p in ESCC tissues compared with adjacent normal tissues (Figure 3C). Furthermore, we detected the negative correlation between the expression of circ\_0087378 and miR-140-3p in ESCC tissues by performing the qRT-PCR analysis (Figure 3D). As expected, the levels of miR-140-3p were downregulated in ESCC cells compared with SHEE cells (Figure 3E).

Next, we utilized a luciferase reporter assay to verify the binding of miR-140-3p to circ\_0087378 in ESCC cells (**Figure 3F**). Overexpression of miR-140-3p inhibited the luciferase activity of circ\_0087378-WT, but did not impact the luciferase activity of the circ\_0087378-MUT (**Figure 3G**). We conducted an RNA pull-down assay using a biotin-tagged circ\_0087378 probe and found that miR-140-43p was purified with the biotin-labeled circ\_0087378 probe compared with the negative control (**Figure 3H**). After that, we performed the RIP assay to pull down circ\_0087378 and miR-140-3p in ESCC cells using anti-Ago2 antibodies or control IgG, following by qRT-PCR analysis. The

results showed that circ\_0087378 and miR-140-3p were significantly enriched in the Ago2 IP fraction in comparison to the IgG control fractions (**Figure 3I**). Collectively, these results supported a direct interaction between circ\_0087378 and miR-140-3p in ESCC cells.

#### Circ\_0087378 Promotes the Proliferation and Invasiveness of ESCC Cells by Sponging miR-140-3p

We questioned whether circ\_0087378 exerts its tumorpromoting effects via sponging miR-140-3p by performing rescue experiments. The transfection with anti-miR-140-3p inhibitor significantly decreased the levels of miR-140-3p in ESCC cells (Figure 4A). Subsequent cell functional assays demonstrated that the inhibition of miR-140-3p restored the proliferative and invasive properties of ESCC cells that were produced by circ\_0087378 knockdown (Figures 4B-F). The flow cytometry analysis indicated that the knockdown of circ\_0087378 increased cell apoptosis, while co-transfection with anti-miR-1403p significantly reduced cell apoptosis compared with the control (Figure 4F). The downregulation of miR-140-3p was more likely to occur in patients with high tumor grade, late-stage, and a high risk of lymph node metastasis (Table 4). These results suggested that circ\_0087378 promotes the proliferation and invasiveness of ESCC cells by sponging miR-140-3p.

### MiR-140-3p Inhibits the Proliferation and Invasion of ESCC Cells by Targeting E2F3

Since these data indicated that circ\_0087378 enhances the aggressive features of ESCC cells *via* miR-140-3p sequestration, we sought to determine whether circ\_0087378 could increase the expression of miR-140-3p target genes. We queried the StarBase



transfected with indicated siRNAs. (**B**, **C**) CCK-8 assays (**B**) and clone colony formation assays (**C**) in ESCC cells after knockdown of circ\_0087378. (**D**, **E**) Cell migration (**D**) and cell invasion (**E**) assays in ESCC cells after circ\_0087378 knockdown. (**F**) Flow cytometry analysis was used to detect ESCC cell apoptosis after knockdown of circ\_0087378. (**G**, **H**) KYSE150 cells transfected with (or without) sh-circ0087378#1 were injected into nude mice. (**G**) Tumor volumes of xenograft tumors were measured. (**H**) Representative images of tumors and tumor weights of xenograft tumors. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

database to identify miR-140-3p target genes, and discovered a miR-140-3p binding site on the 3'-UTR of *E2F3* mRNA (**Figure 5A**). To validate whether E2F3 is a miR-140-3p target gene, ESCC cells were co-transfected with E2F3 3'-UTR-WT or E2F3 3'-UTR-MUT, along with (or without) miR-140-3p mimic. As a result, miR-140-3p mimic significantly decreased the luciferase activities of E2F3 3'-UTR-WT (**Figure 5B**). However, the transfection with miR-140-3p mimic did not significantly impact the luciferase signal of E2F3 3'-UTR-MUT (**Figure 5B**). Moreover, ESCC cells transfected with miR-140-3p mimic expressed lower E2F3 protein levels (**Figure 5C**). Our further studies showed that silencing of circ\_0087378 could lead to an apparent downregulation of E2F3 (**Figure 5D**). However, these

changes were largely prevented after the transfection with antimiR-140-3p inhibitor (**Figure 5D**). These results revealed that circ\_0087378 promoted the expression of E2F3 in ESCC cells by reducing the inhibitory effects of miR-140-3p.

We compared the expression of E2F3 in ESCC tissues and normal tissues by using the TCGA ESCC dataset. E2F3 levels were significantly higher in ESCC tissues *versus* normal tissues (**Figure 5E**). Our qRT-PCR assays revealed an upregulation of E2F3 in ESCC tumor specimens compared with adjacent normal tissues (**Figure 5F**). In agreement with these findings, the levels of circ\_0087378 were positively correlated to the expression of E2F3 expression in ESCC tissue (n = 50) (**Figure 5G**). Meanwhile, highly expressed E2F3 was negatively correlated



and miR-140-3p in ESCC cells. \*\*\*P < 0.001.

with lower miR-140-3p expression (**Figure 5H**). Compared with SHEE cells, the expression of E2F3 was clearly upregulated in ESCC cell lines (**Figure 5I**). Consistent with these results, we found that higher E2F3 expression was positively correlated with large tumor size, high tumor grade, late tumor stage, and the

presence of metastasis in patients with ESCC (**Table 4**). Furthermore, overexpression of miR-140-3p led to decreased cell growth, cell migration and invasion, as well as increased cell apoptosis (**Figures 6A–F**). However, these effects could be significantly abolished by ectopic overexpression of E2F3



transfected with anti-miR-140-3p inhibitor or the control inhibitor. (**B**–**F**) CCK-8 assays (**B**), clone colony formation (**C**), cell migration (**D**), cell invasion (**E**) assays and Flow cytometry analysis (**F**) in ESCC cells transfected with (or without) sh-circ\_0087378#1, along with (or without) anti-miR-140-3p inhibitor. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001; "P < 0.05, "#P < 0.01, "#"P < 0.001.

(Figures 6A-F). These data support the notion that the circ\_0087378/miR-140-3p/E2F3 axis is essential for ESCC growth and progression.

## DISCUSSION

Recent studies have shown that miRNAs and circRNAs participate in the regulation of ESCC initiation and progression (8, 9, 27). For example, circ\_0000337 could sponge miR-670-5p to regulate the migration and invasion of ESCC cells (28). In addition, circ\_0000337 promotes ESCC metastasis by augmenting beta-catenin signaling (29). To date, there were few studies on circ\_0087378 function in ESCC. In this study, we

found that circ\_0087378 was highly expressed in ESCC tumor tissues relative to adjacent normal tissues. Our *in vitro* and *in vivo* results demonstrated that circ\_0087378 performed prooncogenic functions in ESCC. Our results suggest, for the first time, the importance of circ\_0000337 as a key regulator in human ESCC progression.

Several previous studies have shown that miR-140-3p is a critical miRNA that acts as a tumor suppressor in various cancers (30–32). Furthermore, miR-140-3p was shown to be down-regulated in ESCC tissues (21). MiR-140-3p could interact with NRIP1 to inhibit the tumorigenesis of ESCC (24). Consistent with these results, we demonstrated that circ\_0000337 promoted the proliferation and invasion of ESCC cells *via* sponging miR-140-3p.



As an important member of the E2F family, E2F3 affects tumorigenesis and progression in lung cancer (33) and osteosarcoma (34). Furthermore, E2F3 was up-regulated in ESCC tissues (35). Here, our results verified that miR-140-3p directly binds to E2F3 and inhibits its expression in ESCC cells. E2F3 enhances the malignant properties of ESCC cells, and overexpression of E2F3 could reverse the tumor-suppressing functions of miR-140-3p. Moreover, the expression of E2F3 was significantly positively correlated with the levels of circ\_0087378, while E2F3 expression was negatively correlated with the levels of miR-140-3p in ESCC tumor tissues. Taken together, our findings demonstrated that circ\_0087378 promoted the tumorigenesis and progression of ESCC *via* regulating the miR-140-3p/E2F3 axis.

There were certain limitations in our study. We only tested the effects of circ\_0087378 knockdown, but not the influence of circ\_0087378 overexpression on ESCC cells. In addition, our results showed that circ\_0087378 inhibits the function of miR-140-3p, while inhibiting miR-140-3p expression failed to completely eliminate the effects of circ\_0087378 knockdown on ESCC cells. This might be involved in the complexity of the circ\_0087378-miRNA regulatory networks. A previous study has shown that one circRNA can simultaneously target several miRNAs (36), implying that circ\_0087378 might target multiple miRNAs in ESCC cells. Thus, reducing the levels of miR-1403-p may not be enough to abolish the effects of circ\_0087378 knockdown on ESCC cells. Also, one miRNA



was able to bind several targets simultaneously (37). This might account for why overexpressing E2F3 expression did not completely reverse the effects of miR-140-3p on ESCC cells.

In conclusion, our results provide new evidence showing that circ\_0087378 is a novel oncogenic circRNA that exerts its tumor-promoting activities in ESCC through mediating the miR-140-3p/E2F3 axis. This study may offer a potential therapeutic target, circ\_0087378, to broaden the treatment options for human ESCC.

## DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. These data can be found here: the NCBI Gene Expression Omnibus (GSE131969).

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Renmin Hospital of Wuhan University. The

patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the animal ethics committee of Wuhan University.

## **AUTHOR CONTRIBUTIONS**

YC designed the experiments. SK applied the funding. HZ analyzed the public database, designed the study and edited the paper. JW, QW, and YG performed the experiments, HQ analyzed the data. SK and YC wrote the paper. All authors contributed to the article and approved the submitted version.

### FUNDING

This work was supported by the National Natural Science Foundation of China (No. U1604175), National Key R&D Program of China (2018YFC1311300), Independent research project of Wuhan University (2042019kf0103), and the Beijing Kangmeng Charity Foundation (2020HX0026).

## REFERENCES

- 1. Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician (2017) 95:22–8.
- Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. *World J Gastroenterol* (2015) 21:7933–43. doi: 10.3748/wjg.v21.i26.7933
- Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg (2018) 41:210–5. doi: 10.1016/j.asjsur.2016.10.005
- Pan Y, Sun Z, Wang W, Yang Z, Jia J, Feng X, et al. Automatic detection of squamous cell carcinoma metastasis in esophageal lymph nodes using semantic segmentation. *Clin Transl Med* (2020) 10(3):e129. doi: 10.1002/ctm2.129
- Hou X, Wen J, Ren Z, Zhang G. Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer. *Oncotarget* (2017) 8:43571–8. doi: 10.18632/oncotarget.16721
- Zhong R, Chen Z, Mo T, Li Z, Zhang P. Potential Role of circPVT1 as a proliferative factor and treatment target in esophageal carcinoma. *Cancer Cell Int* (2019) 19:267. doi: 10.1186/s12935-019-0985-9
- Cao S, Chen G, Yan L, Li L, Huang X. Contribution of dysregulated circRNA\_100876 to proliferation and metastasis of esophageal squamous cell carcinoma. *Onco Targets Ther* (2018) 11:7385–94. doi: 10.2147/OTT.S177524
- Wang HY, Wang YP, Zeng X, Zheng Y, Guo QH, Ji R, et al. Circular RNA is a popular molecule in tumors of the digestive system (Review). Int J Oncol (2020) 57:21–42. doi: 10.3892/ijo.2020.5054
- Feng Q, Zhang H, Yao D, Chen WD, Wang YD. Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma. Int J Mol Sci (2020) 21(1):258. doi: 10.3390/ijms21010258
- Xu D, Dong P, Xiong Y, Yue J, Konno Y, Ihira K, et al. MicroRNA-361-Mediated Inhibition of HSP90 Expression and EMT in Cervical Cancer Is Counteracted by Oncogenic IncRNA NEAT1. *Cells* (2020) 9(3):632. doi: 10.3390/cells9030632
- Shi Y, Fang N, Li Y, Guo Z, Jiang W, He Y, et al. Circular RNA LPAR3 sponges microRNA-198 to facilitate esophageal cancer migration, invasion, and metastasis. *Cancer Sci* (2020) 111(8):2824–36. doi: 10.1111/cas.14511
- Zou FW, Yang SZ, Li WY, Liu CY, Liu XH, Hu CH, et al. circRNA\_001275 upregulates Wnt7a expression by competitively sponging miR3703p to promote cisplatin resistance in esophageal cancer. *Int J Oncol* (2020) 57:151–60. doi: 10.3892/ijo.2020.5050
- Yuan C, Zhou L, Zhang L, Yin K, Peng J, Sha R, et al. Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer. *Epigenomics* (2019) 11(3):297–321. doi: 10.2217/epi-2018-0147
- 14. Zhao Q, Li JY, Zhang J, Long YX, Li YJ, Guo XD, et al. Role of visfatin in promoting proliferation and invasion of colorectal cancer cells by downregulating SDF-1/CXCR4-mediated miR-140-3p expression. *Eur Rev Med Pharmacol Sci* (2020) 24:5367–77. doi: 10.26355/eurrev\_202005\_21320
- Zhou Y, Wang B, Wang Y, Chen G, Lian Q, Wang H. miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett (2019) 17:3835–41. doi: 10.3892/ol.2019.10038
- Huang H, Wang Y, Li Q, Fei X, Ma H, Hu R. miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9. *Cancer Lett* (2019) 446:81–9. doi: 10.1016/j.canlet.2019.01.007
- DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. *Biochim Biophys Acta* (2002) 1602:131–50. doi: 10.1016/S0304-419X(02)00051-3
- Liu ZL, Bi XW, Liu PP, Lei DX, Wang Y, Li ZM, et al. Expressions and prognostic values of the E2F transcription factors in human breast carcinoma. *Cancer Manag Res* (2018) 10:3521–32. doi: 10.2147/CMAR.S172332
- Fang Z, Lin M, Li C, Liu H, Gong C. A comprehensive review of the roles of E2F1 in colon cancer. Am J Cancer Res (2020) 10:757–68.
- Gao S, Duan H, An D, Yi X, Li J, Liao C. Knockdown of long non-coding RNA LINC00467 inhibits glioma cell progression via modulation of E2F3 targeted by miR-200a. *Cell Cycle* (2020) 19(16):2040–53. doi: 10.1080/ 15384101.2020.1792127
- Yang H, Su H, Hu N, Wang C, Wang L, Giffen C, et al. Integrated analysis of genome-wide miRNAs and targeted gene expression in esophageal squamous cell carcinoma (ESCC) and relation to prognosis. *BMC Cancer* (2020) 20 (1):388. doi: 10.1186/s12885-020-06901-6

- Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. *Clin Cancer Res* (2001) 7:1654–60.
- 24. Chen X, Jiang J, Zhao Y, Wang X, Zhang C, Zhuan L, et al. Circular RNA circNTRK2 facilitates the progression of esophageal squamous cell carcinoma through up-regulating NRIP1 expression via miR-140-3p. *J Exp Clin Cancer Res* (2020) 39(1):133. doi: 10.1186/s13046-020-01640-9
- Liu J, Xue N, Guo Y, Niu K, Gao L, Zhang S, et al. CircRNA\_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway. *Aging (Albany NY)* (2019) 11:12412–27. doi: 10.18632/aging.102580
- 26. Yang B, Du K, Yang C, Xiang L, Xu Y, Cao C, et al. CircPRMT5 circular RNA promotes proliferation of colorectal cancer through sponging miR-377 to induce E2F3 expression. J Cell Mol Med (2020) 24:3431–7. doi: 10.1111/jcmm.15019
- Chen F, Chu L, Li J, Shi Y, Xu B, Gu J, et al. Hypoxia induced changes in miRNAs and their target mRNAs in extracellular vesicles of esophageal squamous cancer cells. *Thorac Cancer* (2020) 11:570–80. doi: 10.1111/1759-7714.13295
- Song H, Xu D, Shi P, He B, Li Z, Ji Y, et al. Upregulated circ RNA hsa\_circ\_0000337 promotes cell proliferation, migration, and invasion of esophageal squamous cell carcinoma. *Cancer Manag Res* (2019) 11:1997– 2006. doi: 10.2147/CMAR.S195546
- 29. Hu X, Wu D, He X, Zhao H, He Z, Lin J, et al. circGSK3beta promotes metastasis in esophageal squamous cell carcinoma by augmenting betacatenin signaling. *Mol Cancer* (2019) 18:160. doi: 10.1186/s12943-019-1095-y
- Hu C, Zou Y, Jing LL. miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1. J Biosci (2020) 45:48. doi: 10.1007/s12038-020-0003-3
- Li L, Zhang F. Novel long noncoding RNA LINC01385 promotes nasopharyngeal carcinoma proliferation via the miR-140-3p/Twist1 signaling pathway. *Cell Cycle* (2020) 19:1352-62. doi: 10.1080/ 15384101.2020.1750133
- He Y, Yang Y, Liao Y, Xu J, Liu L, Li C, et al. miR-140-3p Inhibits Cutaneous Melanoma Progression by Disrupting AKT/p70S6K and JNK Pathways through ABHD2. *Mol Ther Oncolyt* (2020) 17:83–93. doi: 10.1016/j.omto.2020.03.009
- Wang H, Wang L, Zhang S, Xu Z, Zhang G. Downregulation of LINC00665 confers decreased cell proliferation and invasion via the miR-138-5p/E2F3 signaling pathway in NSCLC. *BioMed Pharmacother* (2020) 127:110214. doi: 10.1016/j.biopha.2020.110214
- Li H, Pan R, Lu Q, Ren C, Sun J, Wu H, et al. MicroRNA1455p inhibits osteosarcoma cell proliferation by targeting E2F transcription factor 3. Int J Mol Med (2020) 45:1317–26. doi: 10.3892/ijmm.2020.4504
- 35. Lv J, Guo L, Wang JH, Yan YZ, Zhang J, Wang YY, et al. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus. World J Gastroenterol (2019) 25:233–44. doi: 10.3748/wjg.v25.i2.233
- Bezzi M, Guarnerio J, Pandolfi PP. A circular twist on microRNA regulation. Cell Res (2017) 27:1401–2. doi: 10.1038/cr.2017.136
- Jianwei D, Yuyin L, Youfa D, Zixuan L, Dalei Z, Wensheng C, et al. Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling Pathway. *Int J Biol Sci* (2017) 13:660–8. doi: 10.7150/ijbs.19194

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wang, Wang, Gong, Hu, Zhang, Ke and Chen. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.